TL;DR
This study provides a comprehensive "deep phenotyping" of over 34,000 patients hospitalized with COVID-19 across the US, South Korea, and Spain, detailing their medical histories and medications. By comparing these patients to over 81,000 hospitalized with influenza, the research reveals that COVID-19 patients were generally younger, healthier, and more likely to be male, suggesting that existing influenza-focused vulnerability strategies may need to be adapted for COVID-19.
What Problem Does This Paper Address?
The COVID-19 pandemic presented a significant challenge to healthcare systems worldwide, and understanding the characteristics of hospitalized patients was crucial for effective response and resource allocation. While early studies provided some insights, there was substantial uncertainty regarding the prevalence of comorbidities and prior medication use among COVID-19 patients. Furthermore, it was unclear how these patients systematically differed from those hospitalized during previous influenza seasons. This knowledge gap made it difficult to tailor public health interventions and clinical management strategies effectively. This paper aims to bridge this gap by providing a detailed, multi-continental characterization of COVID-19 patients and a direct comparison to influenza patients.
Methods
The study employed a retrospective cohort design, leveraging routinely collected electronic health records (EHRs), hospital billing data, and insurance claims. A key methodological aspect was the use of the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). This standardized data model allowed for the harmonization of data from diverse sources across different countries, enabling consistent analysis without sharing raw patient-level data. The researchers extracted a wide range of aggregate characteristics, including demographics, pre-existing conditions (identified using SNOMED codes), and medication use (categorized using Anatomical Therapeutic Chemical (ATC) groupings). Medication use was analyzed over different time windows: a year prior to hospitalization, 30 days prior, and on the day of hospitalization. Standardized Mean Differences (SMDs) were calculated to compare characteristics between COVID-19 and influenza cohorts.
Datasets
The study utilized data from multiple sources across three continents:
- United States:
- Columbia University Irving Medical Center (CUIMC)
- Premier Healthcare Database (PHD)
- UCHealth System Health Data Compass (UC HDC)
- Department of Veterans Affairs (VA OMOP)
- South Korea:
- Health Insurance Review & Assessment (HIRA)
- Spain:
- The Information System for Research in Primary Care (SIDIAP)
- HM Hospitales (HM)
These datasets were used to identify:
- 34,128 individuals hospitalized with COVID-19 (December 2019 - April 2020).
- 81,596 individuals hospitalized with influenza (September 2014 - April 2019, with a subset from 2009-2010).
Key Insights and Ideas
- COVID-19 patients are generally "healthier" than influenza patients: A surprising finding was that COVID-19 patients, on average, presented with fewer comorbidities and lower medication use compared to those hospitalized with influenza in previous seasons. This challenges the initial assumption that severe COVID-19 would disproportionately affect individuals with extensive pre-existing conditions, similar to severe influenza.
- Demographic differences are significant: COVID-19 hospitalizations skewed male, particularly in the US and Spain, and were generally younger than influenza hospitalizations. This contrasts with some influenza seasons where older individuals are more severely affected.
- Geographic variation is substantial: The study highlighted significant differences in patient characteristics across the contributing databases and countries, particularly in South Korea where patients were predominantly female and younger. This underscores the importance of context-specific analysis.
- Medication use patterns offer clues: While overall medication use was lower in COVID-19 patients, specific drug classes, like those acting on the renin-angiotensin system, were still commonly used, raising questions about their impact and management during COVID-19 infection.
Key Results
- Patient Cohort: 34,128 COVID-19 patients and 81,596 influenza patients were analyzed.
- Demographics: COVID-19 patients were more typically male (e.g., 94% in VA OMOP) and younger compared to influenza patients. South Korean patients (HIRA) were predominantly female (60%).
- Comorbidities: Prevalence of conditions like asthma, diabetes, and hypertension varied significantly across data sources but were generally comparable or lower in COVID-19 patients compared to influenza patients. For instance, heart disease prevalence in the US ranged from 28% to 48% for COVID-19 patients, while it was higher in some influenza cohorts.
- Medication Use: Between 14% and 33% of COVID-19 patients were taking drugs acting on the renin-angiotensin system in the 30 days prior to hospitalization. Overall medication use was lower in COVID-19 patients compared to influenza patients.
Limitations and Future Work
- Data Quality: The study acknowledges that the reliance on routinely collected data means potential data quality issues, such as underestimation of conditions due to missing codes or misclassification of medication use (e.g., prescribed vs. actually taken).
- Snapshot in Time: The characterization is based on the point of hospital admission, providing a snapshot rather than a complete picture of disease progression or community-level infection.
- Comparison Nuances: Comparing COVID-19 patients to influenza patients across different time periods has inherent limitations, as clinical practices, diagnostic criteria, and even the nature of influenza strains can change over time.
- Future Work: The authors suggest that while existing influenza vulnerability strategies are a good starting point, they need to be broadened to account for the specific characteristics of COVID-19 patients. Further research is needed on the benefits and harms of continued use of medications commonly taken by COVID-19 patients, especially those with potential implications for COVID-19 susceptibility or severity. The study also highlights the need for further research into the consequences of temporarily discontinuing certain medications for cardiovascular risks and mortality.
Summary updated